Thermo Fisher Scientific Inc. $TMO Shares Bought by Argus Investors Counsel Inc.

Argus Investors Counsel Inc. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 3,065 shares of the medical research company’s stock after buying an additional 59 shares during the quarter. Argus Investors Counsel Inc.’s holdings in Thermo Fisher Scientific were worth $1,243,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of TMO. CBIZ Investment Advisory Services LLC lifted its position in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares during the last quarter. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in shares of Thermo Fisher Scientific in the 1st quarter worth about $37,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TMO. HSBC restated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Raymond James Financial reiterated an “outperform” rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, September 7th. Finally, William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. Sixteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $588.35.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $464.18 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77. The firm’s fifty day moving average is $476.70 and its two-hundred day moving average is $447.57. The company has a market cap of $175.28 billion, a P/E ratio of 26.85, a P/E/G ratio of 2.52 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the firm earned $5.37 EPS. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.